Several brokerages have updated their recommendations and price targets on shares of Pfizer (NYSE: PFE) in the last few weeks:
- 7/13/2026 – Pfizer had its price target lowered by BMO Capital Markets from $34.00 to $30.00. They now have an “outperform” rating on the stock.
- 7/13/2026 – Pfizer had its price target lowered by Guggenheim from $36.00 to $35.00. They now have a “buy” rating on the stock.
- 7/10/2026 – Pfizer had its price target lowered by Bank of America Corporation from $27.00 to $26.00. They now have a “neutral” rating on the stock.
- 7/8/2026 – Pfizer had its price target lowered by JPMorgan Chase & Co. from $30.00 to $28.00. They now have a “neutral” rating on the stock.
- 7/6/2026 – Pfizer was downgraded by HSBC Holdings plc from “buy” to “hold”. They now have a $28.00 price target on the stock, down from $32.00.
- 7/6/2026 – Pfizer had its “neutral” rating reaffirmed by Cantor Fitzgerald. They now have a $27.00 price target on the stock.
- 7/4/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/23/2026 – Pfizer had its “outperform” rating reaffirmed by BMO Capital Markets.
- 6/21/2026 – Pfizer was upgraded by Wall Street Zen from “hold” to “buy”.
- 6/13/2026 – Pfizer was downgraded by Wall Street Zen from “buy” to “hold”.
- 6/9/2026 – Pfizer was upgraded by Royal Bank Of Canada from “underperform” to “sector perform”. They now have a $25.00 price target on the stock.
- 6/1/2026 – Pfizer had its “neutral” rating reaffirmed by Cantor Fitzgerald.
- 5/27/2026 – Pfizer had its “neutral” rating reaffirmed by UBS Group AG. They now have a $27.00 price target on the stock.
Pfizer Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.1%. Pfizer’s payout ratio is currently 131.30%.
Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.
See Also
- Five stocks we like better than Pfizer
- No Space For Panic: T-Mobile Shrugs Off The Starlink Threat
- Prepare for the Next Wave of Factory Automation With These 3 Standout Names
- These 3 Water ETFs Could be Quiet Winners From Infrastructure Spending
- The Bond Market Just Sent Amazon a Message Investors Shouldn’t Ignore
Receive News & Ratings for Pfizer Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc and related companies with MarketBeat.com's FREE daily email newsletter.
